How to Cite IWQOL-Lite-Clinical Trials Version©
Kolotkin RL, Williams VSL, Ervin CM, Williams N, Meincke HH, Qin S, von Huth Smith L, Fehnel SE. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clin Obes. 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310.
IWQOL-Lite-Clinical Trials Publications
Kolotkin, R.L., Ervin, C.M., Meincke, H.H., Højbjerre L., Fehnel, S.E. Development of a clinical trials version of the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite Clinical Trials Version): Results from two qualitative studies. Clinical Obesity, 2017 Oct;7(5):290-299. doi: 10.1111/cob.12197.
Kolotkin, R.L., Williams, V.S.L., Ervin, C.M., Williams, N., Meincke, H.H., Qin, S., von Huth Smith, L., Fehnel, S.E. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clinical Obesity, 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310. View supporting tables for this publication.
Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321 (15):1466–1480, Supplement 1.
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17. PMID: 31530667; PMCID: PMC7364672.
Wadden, T.A., Tronieri, J.S., Sugimoto, D., Lund, M.T., Auerbach, P., Jensen, C., Rubino, D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726/.
Garvey, W.T., Birkenfeld, A.L., Dicker, D., et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 Mar 5. pii: dc191745. doi: 10.2337/dc19-1745.
Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. doi:10.1002/oby.22794
Wilding, JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384 (11): 989-1002.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 2:S0140-6736(21)00213-0. doi: 10.1016/S0140-6736(21)00213-0.
Wharton, S, Bjorner, JB, Kushner, RF, et al. Semaglutide 2.4 mg Once Weekly Improves Patient-Reported Outcome Measures of Physical Functioning in Adults with Overweight or Obesity in the STEP 1 Trial. Obesity Facts; 2021;15 (suppl 1): 52-53.
Rubino, DM, Bjorner, JB, Kushner, RF, et al. Beneficial Effect of Semaglutide 2.4 mg Once Weekly on Patient-Reported Outcome Measures of Weight-Related and Health-Related Quality of Life in Adults With Overweight or Obesity in the STEP 1 Trial. Obesity Facts; 2021;15 (suppl 1): 118-119.
Rubino, DM, Færch, L, Meincke, H, et al. (2021). Semaglutide 2.4 mg Improves Health-Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial. Diabetes. 70. 84-OR. 10.2337/db21-84-OR.
Kolotkin, RL, Williams, VSL, von Huth Smith, L, et al. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life–Lite Clinical Trials Version (IWQOL-Lite-CT). Clinical Obesity. 2021 Jul 22:e12477. doi: 10.1111/cob.12477.
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinology 2022; published online Feb 4. https://doi. org/10.1016/S2213-8587(22)00008-0.
Boye, K, Thieu, V, Yu, M, Sapin, H. Higher weight loss is associated with improved quality of life in patients with type 2 diabetes—SURPASS program. Diabetes 2022;71(Supplement_1):47-LB. https://doi.org/10.2337/db22-47-LB.
Boye, KS, Yu, M, Liu, B, et al. Patient reported outcomes for tirzepatide versus semaglutide in participants with T2D from the SURPASS-2 Trial. Diabetes Research and Clinical Practice. Volume 186; Supplement 1, 109697, April 01, 2022. https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(22)00509-5/fulltext
le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2022;1‐15. doi:10.1002/oby.23612
Poon, JL., Marshall, C., Johnson, C. et al. A qualitative study to examine meaningful change in physical function associated with weight-loss. Qual Life Res 32, 1329–1340 (2023). https://doi.org/10.1007/s11136-022-03191-2
Kolotkin, R.L., Jeppesen, O., Baker-Knight, J., Lee, S.Y., Tokita, A., Kadowaki, T. Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial. Clinical Obesity, 2023, doi.org/10.1111/cob.12589. https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.12589
Kolotkin, R.L., Williams, V.S.L., Ervin, C.M., Williams, N., Meincke, H.H., Qin, S., von Huth Smith, L., Fehnel, S.E. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clinical Obesity, 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310. View supporting tables for this publication.
Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321 (15):1466–1480, Supplement 1.
Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E; PIONEER 8 Investigators. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019 Dec;42(12):2262-2271. doi: 10.2337/dc19-0898. Epub 2019 Sep 17. PMID: 31530667; PMCID: PMC7364672.
Wadden, T.A., Tronieri, J.S., Sugimoto, D., Lund, M.T., Auerbach, P., Jensen, C., Rubino, D. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring). 2020 Mar;28(3):529-536. doi: 10.1002/oby.22726/.
Garvey, W.T., Birkenfeld, A.L., Dicker, D., et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 Mar 5. pii: dc191745. doi: 10.2337/dc19-1745.
Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. doi:10.1002/oby.22794
Wilding, JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384 (11): 989-1002.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 2:S0140-6736(21)00213-0. doi: 10.1016/S0140-6736(21)00213-0.
Wharton, S, Bjorner, JB, Kushner, RF, et al. Semaglutide 2.4 mg Once Weekly Improves Patient-Reported Outcome Measures of Physical Functioning in Adults with Overweight or Obesity in the STEP 1 Trial. Obesity Facts; 2021;15 (suppl 1): 52-53.
Rubino, DM, Bjorner, JB, Kushner, RF, et al. Beneficial Effect of Semaglutide 2.4 mg Once Weekly on Patient-Reported Outcome Measures of Weight-Related and Health-Related Quality of Life in Adults With Overweight or Obesity in the STEP 1 Trial. Obesity Facts; 2021;15 (suppl 1): 118-119.
Rubino, DM, Færch, L, Meincke, H, et al. (2021). Semaglutide 2.4 mg Improves Health-Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial. Diabetes. 70. 84-OR. 10.2337/db21-84-OR.
Kolotkin, RL, Williams, VSL, von Huth Smith, L, et al. Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life–Lite Clinical Trials Version (IWQOL-Lite-CT). Clinical Obesity. 2021 Jul 22:e12477. doi: 10.1111/cob.12477.
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinology 2022; published online Feb 4. https://doi. org/10.1016/S2213-8587(22)00008-0.
Boye, K, Thieu, V, Yu, M, Sapin, H. Higher weight loss is associated with improved quality of life in patients with type 2 diabetes—SURPASS program. Diabetes 2022;71(Supplement_1):47-LB. https://doi.org/10.2337/db22-47-LB.
Boye, KS, Yu, M, Liu, B, et al. Patient reported outcomes for tirzepatide versus semaglutide in participants with T2D from the SURPASS-2 Trial. Diabetes Research and Clinical Practice. Volume 186; Supplement 1, 109697, April 01, 2022. https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(22)00509-5/fulltext
le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2022;1‐15. doi:10.1002/oby.23612
Poon, JL., Marshall, C., Johnson, C. et al. A qualitative study to examine meaningful change in physical function associated with weight-loss. Qual Life Res 32, 1329–1340 (2023). https://doi.org/10.1007/s11136-022-03191-2
Kolotkin, R.L., Jeppesen, O., Baker-Knight, J., Lee, S.Y., Tokita, A., Kadowaki, T. Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial. Clinical Obesity, 2023, doi.org/10.1111/cob.12589. https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.12589